MyMD Pharmaceuticals Inc (MYMD)

[Twice Worthy]

Dosing completed with Sarcopenia cohorts in the blinded study of MYMD-1 drug. FDA's Safety Committee will be reviewing the results of the blinded study. The results will be shared with MYMD once completed and, the company would then post the results from the study. The results from the study could be very significant and could begin to propel MYMD stock higher based on the new drug's effect with patients. The study results should be posted in a few weeks ... very much looking forward to them and the effect on MYMD's share price.